-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Climb Bio, Raises Price Target to $20

Benzinga·06/11/2026 15:41:51
Listen to the news
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $19 to $20.